Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Liver Neoplasms 2Glioma 2Glioblastoma 2Carcinoma, Hepatocellular 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Prostatic Neoplasms 1Oligodendroglioma 1Neoplasms 1Liver Neoplasms, Experimental 1Gliosarcoma 1Disease Progression 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Brain Neoplasms 1Astrocytoma 1Adenoma, Liver Cell 1

Interventions

Doxorubicin 8Cisplatin 5Chemotherapy, Adjuvant 5Thalidomide 4Radiofrequency Ablation 4Neoadjuvant Therapy 4Melphalan 4Cyclophosphamide 4Carboplatin 4tremelimumab 3fludarabine 3aldesleukin 3Sorafenib 3Irinotecan 3Capecitabine 3durvalumab 2carotuximab 2Temozolomide 2Tamoxifen 2Oxaliplatin 2Leucovorin 2Gemcitabine 2Fluorouracil 2Fluorodeoxyglucose F18 2Epirubicin 2Cryosurgery 2Biopsy 2Bevacizumab 2sargramostim 1ropidoxuridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Liver Neoplasms × carotuximab × Clear all
NCT01306058 2019-01-23

Sorafenib and TRC105 in Hepatocellular Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
27 enrolled 32 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Liver Neoplasms, Experimental, Adenoma, Liver Cell

NCT01375569 2017-07-28

TRC105 for Liver Cancer That Has Not Responded to Sorafenib

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
11 enrolled 10 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡